Mark DiPaolo
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
Highest-materiality recent filing
Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M
Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved
Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).
Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback
Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).
Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15
Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.
Innoviva Q1 net loss $46.6M on $78.8M investment write-down; IST sales up 52%
Net loss of $46.6M ($0.74/share) vs net income of $36.5M in Q1 2024 due to $78.8M unfavorable fair value changes on equity investments.
Innoviva Q4 GSK royalties $66M, IST sales up 47% YoY; ZEVTERA launch mid-2025
Q4 GSK royalties $66.0M; full year $255.6M vs $252.7M in 2023.
Innoviva Q3 2024 royalty revenue $60.5M (+6% YoY); net product sales $27.8M; net income $1.2M
Royalty revenue from GSK $60.5M, up 6% YoY; core royalty platform continued strong performance.
Innoviva Q2 2024: net loss $34.7M on investment fair-value hit; royalty revenue $67.2M
GSK royalty revenue $67.2M vs $65.7M YoY; net product sales $21.7M (+38% YoY).
Net income $36.5M ($0.58 basic EPS) vs $34.9M ($0.51) in Q1 2023.
Innoviva Q4 net income $61.5M, royalty revenue $69.6M; product sales up 35% YoY
Q4 net income $61.5M ($0.97 EPS) vs $68.3M loss in Q4 2022; full-year net income $179.7M.
Innoviva's zoliflodacin meets primary endpoint in Phase 3 gonorrhea trial
Zoliflodacin met primary efficacy endpoint with non-inferiority to ceftriaxone+azithromycin in urogenital gonorrhea (point estimate 5.3% difference, 95% CI 1.4%-8.7%).
GSK royalty revenue $57.0M (Q3 2023) vs $65.6M (Q3 2022); net product sales $13.7M.
Innoviva appoints Stephen Basso as CFO with $450K salary, $100K signing bonus
Stephen Basso appointed CFO effective August 21, 2023; brings 30+ years pharma/finance leadership experience.
Innoviva receives Nasdaq notice for audit committee non-compliance after director resignation
Nasdaq notified Innoviva on Aug 2, 2023, that Audit Committee has only 2 independent directors after Dr. Deborah L. Birx resigned July 10.
Innoviva Q2 2023: GSK royalties $65.7M, XACDURO FDA approved, net income $1.3M
GSK royalties of $65.7M (RELVAR/BREO $54.4M, ANORO $11.3M) vs $111.7M in Q2 2022 due to TRELEGY royalty sale.
Innoviva Q1 net income $34.9M ($0.51 EPS); GSK royalties $60.3M
Net income $34.9M ($0.51 basic EPS) vs $15.8M ($0.23) YoY.
Innoviva reports Q4 2022 royalties of $54.7M, pre-tax loss of $64.7M on $85.4M fair-value decline
Gross royalty revenues of $54.7M from GSK for RELVAR/BREO and ANORO ELLIPTA in Q4 2022.
Innoviva Q3 gross royalties $65.6M, income before taxes surges to $286.4M on TRC sale gain
Gross royalty revenues of $65.6M (flat YoY) from RELVAR/BREO ($55.7M) and ANORO ($9.9M).
Innoviva completes sale of 15% stake in Theravance Respiratory to Royalty Pharma for $281.9M upfront
Sold 750 Class A and 750 Class C Units (15% ownership) of TRC to Royalty Pharma Investments for $281.9M upfront.
Innoviva completes acquisition of La Jolla Pharmaceutical for $6.23 per share
Tender offer accepted 21,703,224 shares (~87.03% of outstanding) at $6.23 per share, no interest.
Innoviva Q2 royalties up 7% to $111.7M; acquires Entasis, agrees to buy La Jolla
Royalties increased 7% to $111.7M in Q2 2022 vs Q2 2021.
Closed sale of 750 Class A and 750 Class C units of Theravance Respiratory Company, LLC to Royalty Pharma Investments 2019 ICAV.
Innoviva sells 15% TRC stake to Royalty Pharma for ~$282M upfront plus $50M milestone
Upfront cash payment of $282M; potential $50M sales-based milestone payment.
Innoviva to acquire La Jolla Pharmaceutical for $6.23/share in cash, ~$149M EV
Offer price $6.23/share ($5.95 base + $0.28 from non-core asset sale); 70% premium to 30-day VWAP.
Innoviva completes acquisition of Entasis Therapeutics for $2.20/share, total ~$42.4M
Acquisition closed on July 11, 2022; Entasis becomes wholly-owned subsidiary of Innoviva.
Innoviva to acquire Entasis Therapeutics for $2.20/share cash tender offer
Offer price of $2.20 per share; all-cash transaction valued at implied equity value of ~$80M (based on 36.4M shares outstanding).
Innoviva Q1 royalties up 5% to $93.5M; invested $45M in Armata, $15M in Entasis
Gross royalty revenues of $93.5M (+5% YoY); TRELEGY sales up 33% to $450.9M.
Innoviva dismisses Grant Thornton, hires Deloitte as auditor
Audit Committee dismissed Grant Thornton effective March 25, 2022; Deloitte appointed for FY 2022.
Innoviva closes additional $36M of 2.125% convertible notes due 2028; total notes now $261M
Issued $36M aggregate principal additional convertible notes; net proceeds ~$34.5M after discounts and expenses.
Innoviva closes $225M 2.125% convertible senior notes due 2028; repurchases $144.8M of 2023 notes
Issued $225M principal of 2.125% convertible notes due March 15, 2028; initial conversion price $26.22 (35% premium to $19.42 close on March 2, 2022).
Innoviva Q4 2021 royalties up 18% to $111.1M; announces $45M strategic investment in Armata
Gross royalty revenues $111.1M in Q4 2021 (+18% YoY); full year 2021 $405.7M (+19%).
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
On May 18, 2026, following the resignations of Messrs. Small and DiPaolo, the Board elected Josephine Linden to serve as a member of the Board of Directors (the “Linden Effective Date”).
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
On and effective as of April 29, 2024 (the “Small Effective Date”), Innoviva, Inc. (the “Company”) appointed Derek Small, to its Board of Directors (the “Board”).
On August 25, 2023, Innoviva, Inc. (the “Company”) announced the hiring and appointment of Stephen Basso, age 57, Chief Financial Officer of the Company, effective as of August 21, 2023.
On July 10, 2023, Deborah L. Birx, a member of the Board of Directors of Innoviva, Inc. (the “Board”) and chair of the Audit Committee, resigned from the Board, including the committees of the Board of which she is a member, effective as of July 10, 2023
George Bickerstaff, III, Chairman of the Board, notified the Board of Directors (the “Board”) of Innoviva, Inc. that he will retire from the Board, including the committees of the Board of the Company of which he is a member, at the end of his current term at the 2023 Annual Meeting of shareholders.
On December 29, 2022, Innoviva, Inc. (the “Company”) appointed Sapna Srivastava, Ph. D., to its Board of Directors (the “Board”), effective January 1, 2023 (the “Srivastava Effective Date”).
Max materiality 0.85 · Median 0.65 · Most common event earnings